Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Change in Account Payables (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Change in Account Payables for 13 consecutive years, with -$232000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables rose 6.07% to -$232000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$137000.0, a 52.43% increase, with the full-year FY2025 number at -$137000.0, up 52.43% from a year prior.
  • Change in Account Payables was -$232000.0 for Q4 2025 at Ekso Bionics Holdings, down from $216000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $1.8 million in Q4 2021 to a low of -$882000.0 in Q2 2022.
  • A 5-year average of -$11100.0 and a median of -$113000.0 in 2021 define the central range for Change in Account Payables.
  • Biggest YoY gain for Change in Account Payables was 1287.5% in 2025; the steepest drop was 326.91% in 2025.
  • Ekso Bionics Holdings' Change in Account Payables stood at $1.8 million in 2021, then crashed by 66.57% to $602000.0 in 2022, then crashed by 209.63% to -$660000.0 in 2023, then soared by 62.58% to -$247000.0 in 2024, then rose by 6.07% to -$232000.0 in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Change in Account Payables are -$232000.0 (Q4 2025), $216000.0 (Q3 2025), and -$565000.0 (Q2 2025).